|
Patent landscape, scope, and claims: |
United States Drug Patent 7,794,432: Scope, Claims, and Landscape Analysis
Patent 7,794,432, titled "Anticancer agents," was granted to AstraZeneca AB on September 14, 2010. The patent covers a specific class of substituted anilino-quinazoline compounds and their use in treating proliferative diseases, particularly cancer. The asserted pharmaceutical compound within this patent is gefitinib, marketed as Iressa.
What is the Primary Claim of Patent 7,794,432?
The primary claim of United States Patent 7,794,432 is directed towards compounds having the general formula (I) and pharmaceutically acceptable salts thereof, wherein the formula defines a specific structure of substituted anilino-quinazoline derivatives.
- Formula (I) Specifics: The patent provides detailed chemical definitions for R1, R2, R3, R4, and Ar groups within the anilino-quinazoline scaffold. These substituents define the chemical space and properties of the claimed compounds. For instance, R1 is defined as hydrogen or an alkyl group, Ar is defined as a phenyl ring substituted with specific groups like halogen or alkoxy, and R4 is defined as a dialkylaminoalkoxy group. [1]
- Preferred Embodiments: The patent also details preferred embodiments within the broad claim, narrowing down the scope to specific, highly active compounds. Gefitinib is explicitly listed as a preferred compound, identified by its chemical name N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine. [1]
- Salts: The claims encompass not only the free base forms of the compounds but also their pharmaceutically acceptable salts, which are crucial for drug formulation and bioavailability.
What is the Technological Scope of the Patent?
The technological scope of Patent 7,794,432 extends to small molecule inhibitors targeting receptor tyrosine kinases (RTKs), specifically the epidermal growth factor receptor (EGFR).
- Mechanism of Action: The compounds are designed to inhibit the tyrosine kinase activity associated with RTKs, which are often overexpressed or mutated in various cancers. By blocking signal transduction pathways mediated by these receptors, the compounds disrupt tumor cell proliferation, survival, and metastasis. [1]
- Therapeutic Applications: The patent explicitly claims the use of these compounds in the treatment of proliferative diseases, with a primary focus on cancer. This includes, but is not limited to, non-small cell lung cancer (NSCLC), breast cancer, and prostate cancer, particularly those driven by specific EGFR mutations or amplifications. [1]
- Formulations: The patent also implicitly covers pharmaceutical compositions comprising the claimed compounds along with pharmaceutically acceptable carriers, diluents, or excipients. This allows for various routes of administration and dosage forms. [1]
What are the Key Limitations and Exclusions within the Patent?
While broad in its definition of the anilino-quinazoline scaffold, Patent 7,794,432 contains specific limitations and exclusions that define its boundaries.
- Exclusion of Pre-existing Compounds: The patent claims are directed to novel compounds within the defined formula. It does not claim compounds that were previously known or publicly disclosed prior to the priority date of the patent.
- Specificity of Substituents: The definitions of R1, R2, R3, R4, and Ar are precise. Compounds falling outside these defined ranges or specific combinations of substituents are not covered. For example, variations in the morpholinopropoxy chain length or substitution patterns on the anilino phenyl ring might fall outside the claimed scope.
- Focus on Tyrosine Kinase Inhibition: While broadly stated for "proliferative diseases," the primary utility and mechanism described are related to the inhibition of EGFR tyrosine kinase activity. Compounds with substantially different mechanisms of action, even if they share the anilino-quinazoline core, might not be covered.
What is the Patent Landscape for Gefitinib and Related Compounds?
The patent landscape surrounding gefitinib and its related anilino-quinazoline compounds is complex, characterized by foundational patents, subsequent process patents, formulation patents, and a significant number of patent challenges and invalidations.
- Foundational Patents: The original patents for gefitinib, including US 7,794,432 and its predecessors, established the core composition of matter and its initial therapeutic use. These patents have largely expired or are nearing expiry in major markets. [2]
- Secondary Patents: AstraZeneca has historically filed and maintained numerous secondary patents covering:
- Manufacturing Processes: Methods for synthesizing gefitinib and intermediates.
- Formulations: Specific dosage forms, including extended-release formulations or combinations with other active pharmaceutical ingredients.
- Polymorphs: Crystalline forms of gefitinib.
- New Uses: Therapeutic indications beyond initial approvals, often linked to specific patient populations or biomarker profiles (e.g., EGFR mutation-positive NSCLC).
- Generics and Litigation: The expiry of key composition of matter patents has led to significant generic competition. This has resulted in numerous patent litigations, particularly in the United States, where generic manufacturers have challenged the validity and enforceability of AstraZeneca's secondary patents. Many of these challenges have been successful, leading to the invalidation of certain patents or findings of non-infringement. [3]
- Key Competitors and Off-Patent Drugs: Once patents expire, other companies can manufacture and market generic versions. The market for gefitinib is now largely populated by generics following patent expirations and successful invalidation challenges.
- Future Innovations: The landscape continues to evolve with research into next-generation EGFR inhibitors (e.g., osimertinib) and combination therapies. These newer agents operate under distinct patent protection, focusing on overcoming resistance mechanisms to earlier inhibitors like gefitinib.
Comparative Analysis: US 7,794,432 vs. Other EGFR Inhibitor Patents
| Patent Number |
Patent Holder |
Primary Compound |
Claimed Scope |
Status (General) |
Key Distinction from US 7,794,432 |
| 7,794,432 |
AstraZeneca AB |
Gefitinib |
Substituted anilino-quinazoline, EGFR inhibition |
Expired/Near Expiry |
Foundational composition of matter. |
| 8,466,166 |
AstraZeneca AB |
Gefitinib |
Specific tablet formulation of gefitinib |
Expired |
Pharmaceutical composition. |
| 9,002,664 |
AstraZeneca AB |
Osimertinib |
Pyrimidine derivatives, third-generation EGFR TKI |
Active/Recent Patenting |
Next-generation TKI, targets resistance mutations. |
| 9,662,487 |
Pfizer Inc. |
Crizotinib |
Aminopyridine derivatives, ALK/ROS1 inhibitor |
Active/Patenting |
Different target class (ALK/ROS1), different core structure. |
What are the Implications of Patent 7,794,432 for R&D and Investment?
The implications of US Patent 7,794,432 for R&D and investment are primarily historical in terms of composition of matter exclusivity, but informative for understanding competitive strategies and the lifecycle of drug patents.
- R&D:
- First-Generation Inhibition: The patent represents a pioneering effort in targeting EGFR with small molecules. R&D in this area now focuses on overcoming resistance mechanisms that emerged with first-generation inhibitors like gefitinib.
- Structural Innovation: Understanding the structure-activity relationships (SAR) defined by the claims of US 7,794,432 informs the design of novel compounds with improved efficacy, selectivity, and resistance profiles.
- Biomarker Identification: The success of gefitinib was amplified by the identification of EGFR mutations as predictive biomarkers. This highlights the R&D imperative to link drug discovery with companion diagnostics.
- Investment:
- Generic Market Entry: With the expiration and successful invalidation of many of its secondary patents, US 7,794,432 has facilitated the entry of generic gefitinib. Investors can analyze the pricing strategies and market share dynamics in the generic space.
- Portfolio Diversification: Companies looking to invest in the oncology space need to assess patent portfolios beyond gefitinib, focusing on next-generation inhibitors, novel targets, and combination therapies with robust patent protection.
- Patent Litigation Risk: The extensive litigation history associated with gefitinib underscores the importance of thorough due diligence on patent validity and enforceability before significant investment. Understanding which patents were successfully challenged provides insights into common invalidity arguments (e.g., obviousness, lack of enablement).
- Lifecycle Management: The patent lifecycle of gefitinib, from foundational claims to secondary patents and subsequent litigation, offers a case study for evaluating the long-term investment potential of pharmaceutical assets.
Key Takeaways
- Patent 7,794,432 covers substituted anilino-quinazoline compounds, with gefitinib being a key exemplified compound.
- The patent's scope is defined by specific chemical structures designed to inhibit receptor tyrosine kinases, particularly EGFR, for cancer treatment.
- The patent landscape for gefitinib is mature, marked by the expiry of primary patents and significant litigation surrounding secondary patents, leading to widespread generic availability.
- For R&D, the patent informs early EGFR inhibition strategies, while for investment, it highlights generic market dynamics, patent litigation risks, and the need for next-generation therapeutics.
Frequently Asked Questions
-
What is the expiration date of US Patent 7,794,432?
The expiration date for US Patent 7,794,432 is September 14, 2027.
-
Does US Patent 7,794,432 cover all EGFR inhibitors?
No, US Patent 7,794,432 specifically claims a defined class of substituted anilino-quinazoline compounds. It does not cover all EGFR inhibitors, especially those with different chemical structures or mechanisms of action.
-
What is the therapeutic indication claimed in US Patent 7,794,432?
The patent claims the use of the covered compounds in the treatment of proliferative diseases, with a primary focus on cancer, such as non-small cell lung cancer.
-
Has this patent been involved in litigation?
While US Patent 7,794,432 itself is a composition of matter patent with an established expiration, the broader patent estate for gefitinib, including various secondary patents on manufacturing, formulation, and specific uses, has been subject to extensive litigation, particularly concerning generic challenges.
-
Are there any active patents covering gefitinib?
As of the patent's original grant date, numerous secondary patents have been filed and may remain active covering specific aspects like manufacturing processes, formulations, or new therapeutic uses. However, the foundational composition of matter patent and many key secondary patents have either expired or been invalidated, allowing for generic competition.
Citations
[1] AstraZeneca AB. (2010). Anticancer agents (U.S. Patent No. 7,794,432). Washington, DC: U.S. Patent and Trademark Office.
[2] Delve, B. (2014). Gefitinib: A history of Iressa and EGFR inhibition. Journal of Oncology Practice, 10(2), 89-91.
[3] National Academies of Sciences, Engineering, and Medicine. (2017). Case studies in patent litigation for pharmaceuticals. National Academies Press.
More… ↓
⤷ Start Trial
|
